2. Areas of Work Regulatory System Strengthening Access and Rational Use Blood, Radiological and Pharmaceutical Services

3. Regulatory System Strengthening Systems approach/ Across all technologies. Contemplate the specificities off specific technologies Exchange of Information: REPs (regulatory exchange platform secure) Pan American Journal of Public Health: special issue (june 2016) PANDRH: new Strategic Plan, Conference :October 2016, MEX CRS: Caribbean Regulatory System Title of the Presentation2

4. Regulatory Strengthening: Assessment, monitor and evaluation

5. Access and Rationale Use New doc on developing a Pharmaceutical Policy Rational Use Strategy for PAHO MS Agreement with GF on Supply chain management strengthening: direct TC for target countries Title of the Presentation4

6. Growing Participation of Member States

7. SF: types of commodities and criteria for selection 6 WHO Essential Medicines Diagnostics Vector control Other Strategic Medicines Evidence- informed Cost- effectiveness Equity/ vulnerability Public Health impact

8. 7 Pooling Demand / Reducing Price

9. EFAVIRENZ 600MG/ EMTRICITABINE 200MG/ TENOFOVIR 300MG and EFAVIRENZ 600MG/ LAMIVUDINE 300MG/ TENOFOVIR DISOPROXIL FUMARATE 300MG Supporting Expansion of Treatment and Care

10. SF Trends 2005-2015 : Capitalization Account growth 200720082009201020112012201320142015 # Loans11203565 11

11. Products with several competitive (multisource) alternatives Strategic Fund pools demand for countries, seek qualified generic/multisource sources, and lower price through improved competition. Products with supply issues due to lack of commercial interest Strategic Fund pools demand, and negotiates with suppliers to stabilize supply and the market. Strategic Fund facilitates supply of priority donations for neglected diseases. Products under patent protection (monopolies and/or oligopolies) Strategic Fund informs on price trends, and negotiate directly with suppliers. Strategic Fund supports/establishes the necessary linkages with country led negotiations to facilitate procurement. Collective Action to improve Access

12. Mercosur and associated countries price negotiations o Led by MS o Hep C manufacturers o Price for entire region, through SF Access and rational use of high cost and strategic medicines and other health technologies Title of the Presentation11